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New Carbapenem-Resistant Enterobacteriaceae Warrant 
Additional Action by Healthcare Providers
Summary
Carbapenem-resistant Enterobacteriaceae (CRE) are untreatable or difficult-to-treat multidrug- 
resistant organisms that are emerging in the United States. Because of increased reports of these 
multidrug-resistant organisms, CDC is alerting clinicians about the need for additional 
prevention steps regarding CRE. Key points include:
• While still uncommon, reports of unusual forms of CRE (e.g., New Delhi Metallo-P- 
lactamase and Verona Integron-mediated Metallo-P-lactamase) in the United States are 
increasing. Of the 37 unusual forms of CRE that have been reported in the United States, the 
last 15 have been reported since July, 2012.
• This increase highlights the need for U.S. healthcare providers to act aggressively to prevent 
the emergence and spread of these unusual CRE organisms.
• Current CDC guidance includes key elements of CRE prevention (e.g., use of Contact 
Precautions) in healthcare settings.
• Because the vast majority of these unusual organisms were isolated from patients who 
received overnight medical treatment outside of the United States, additional measures 
described in this HAN advisory are now recommended to be taken when such patients are 
hospitalized in the United States.
Background
Klebsiella species and Escherichia coli are examples of Enterobacteriaceae, a family of bacteria 
that normally live in water, soil, and the human gut. CRE are Enterobacteriaceae that have 
developed high levels of resistance to antibiotics, including last-resort antibiotics called 
carbapenems. CRE infections most commonly occur among patients who are receiving 
antibiotics and significant medical treatment for other conditions.
Although there are a large number of mechanisms that can lead to carbapenem resistance among 
Enterobacteriaceae, the production of an enzyme that breaks down broad-spectrum carbapenem
antibiotics (carbapenemases) has emerged as an important mechanism in the United States over 
the last decade. Most carbapenemase-producing CRE in the United States produce a 
carbapenemase called Klebisellapneumoniae carbapenemase, or KPC, which was first reported 
in 2001 and has been found in many different types of Gram-negative bacteria.
KPC-producing Enterobacteriaceae appear to have spread throughout the United States since 
2001 but still remain relatively uncommon in most hospitals. Enterobacteriaceae producing other 
carbapenemases, such as New Delhi Metallo-ß-lactamase (NDM) and the Verona Integron- 
mediated Metallo-ß-lactamase (VIM), have been very uncommon in the United States but are 
more common in other parts of the world. Many countries may not be actively looking for CRE; 
therefore, it is unclear which countries have experienced unusual carbapenemases (e.g., NDM, 
VIM) and it is difficult to know their overall incidence at any given time. The vast majority of 
CRE producing non-KPC carbapenemases reported to CDC were isolated from patients with a 
history of an overnight stay in a healthcare facility outside the United States.
Recommendations
CDC continues to recommend that facilities follow the CDC guidance for preventing the spread 
of CRE in healthcare settings (http://www. cdc. gov/hai/organisms/cre/cre-toolkit/index.html). 
Facilities should:
• Ensure that the patient is on Contact Precautions.
• Reinforce and evaluate adherence to hand hygiene and Contact Precautions for healthcare 
personnel who come into contact with the patient (e.g., enter the patient’s room).
• Since clinical cultures will identify only a minority of patients with CRE, screen 
epidemiologically linked patient contacts for CRE colonization with stool, rectal, or 
perirectal cultures. At a minimum, this should include persons with whom the CRE patient 
shared a room but could also include patients who were treated by the same healthcare 
personnel. A laboratory-based screening protocol is available here: 
(http://www.cdc.gov/HAI/pdfs/labSettings/Klebsiella or Ecoli.pdf).
• Should the patient be transferred to another healthcare facility, ensure that the presence of 
CRE colonization or infection is communicated to the accepting facility. An example transfer 
form is available here
(http://www. cdc. gov/HAI/toolkits/InterfacilityTransferCommunicationForm11 -2010.pdf).
• Dedicate rooms and staff to CRE patients when possible. It is preferred that staff caring for 
CRE patients do not also care for non-CRE patients.
• Remove temporary medical devices as soon as they are no longer needed.
In addition to that guidance, CDC now also recommends the following:
• When a CRE is identified in a patient (infection or colonization) with a history of an 
overnight stay in a healthcare facility (within the last 6 months) outside the United States,
send the isolate to a reference laboratory for confirmatory susceptibility testing and test to 
determine the carbapenem resistance mechanism; at a minimum, this should include 
evaluation for KPC and NDM carbapenemases.
• For patients admitted to healthcare facilities in the United States after recently being 
hospitalized (within the last 6 months) in countries outside the United States, consider each 
of the following:
o Perform rectal screening cultures to detect CRE colonization. 
o Place patients on Contact Precautions while awaiting the results of these screening 
cultures.
Further information about the prevention of CRE transmission is available in CDC’s CRE toolkit
(http://www.cdc.gov/hai/organisms/cre/cre-toolkit/index.html).
The Centers for Disease Control and Prevention (CDC) protects people's health and safety by 
preventing and controlling diseases and injuries; enhances health decisions by providing 
credible information on critical health issues; and promotes healthy living through strong 
partnerships with local, national and international organizations.
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